NU553 Asthma Lecture Notes

NU553 Asthma Lecture Notes

Student Name

Purdue University Global

NU553 Advanced Pharmacology and Pharmacotherapeutics

Prof. Name:

Date

Evidence-Based Pharmacologic Management of Asthma, COPD, Pneumonia, Tuberculosis, and Tobacco Dependence

Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis (TB), and tobacco dependence require evidence-based diagnosis, appropriate medication selection, and ongoing patient education. The most effective respiratory disease management approach combines guideline-directed pharmacologic therapy, lifestyle interventions, monitoring, and adherence strategies to reduce symptoms, prevent complications, and improve long-term outcomes. Asthma treatment primarily focuses on controlling airway inflammation with inhaled corticosteroids, COPD management emphasizes bronchodilation and smoking cessation, pneumonia therapy depends on infection severity and causative organisms, tuberculosis requires prolonged multidrug therapy, and tobacco cessation relies on behavioral support combined with pharmacologic interventions.

Respiratory conditions remain a major cause of morbidity worldwide, making accurate assessment and individualized treatment essential. Healthcare providers must understand medication mechanisms, treatment guidelines, adverse effects, and patient-specific factors when developing respiratory care plans.

Asthma: Pathophysiology and Treatment Goals

Asthma is a chronic inflammatory disorder of the airways characterized by airway hyperresponsiveness, inflammation, and reversible airflow obstruction. Patients commonly experience intermittent episodes of:

• Wheezing

• Shortness of breath

• Chest tightness

• Coughing, especially at night or early morning

Unlike COPD, asthma-related airflow limitation is usually reversible with appropriate treatment. The primary goals of asthma management are to:

• Achieve and maintain symptom control

• Prevent acute exacerbations

• Preserve normal lung function

• Minimize medication-related adverse effects

• Improve quality of life

Asthma severity is categorized based on symptom frequency, nighttime awakenings, rescue medication use, and lung function measurements.

Classification of Asthma Severity

Asthma is commonly classified into four categories:

Treatment decisions should be based on both asthma severity and level of control. Patients require regular reassessment because asthma symptoms and medication needs may change over time.

Short-Acting Beta-Agonists (SABAs): Rescue Therapy for Acute Symptoms

Short-acting beta-agonists (SABAs) are rapid-acting bronchodilators used for immediate relief of asthma symptoms. They work by stimulating beta-2 adrenergic receptors in airway smooth muscle, causing relaxation and rapid bronchodilation.

Common SABA Medications

Examples include:

• Albuterol (Ventolin®, ProAir®)

• Levalbuterol (Xopenex®)

Clinical Uses of SABAs

SABAs are commonly used for:

• Acute asthma symptoms

• Sudden episodes of wheezing

• Exercise-induced bronchospasm

• Temporary relief of shortness of breath

Although SABAs effectively relieve acute symptoms, they do not treat the underlying airway inflammation responsible for asthma progression.

Current asthma guidelines recommend avoiding SABA-only treatment because frequent SABA use is associated with increased risk of severe exacerbations. Controller therapy containing inhaled corticosteroids is preferred for long-term asthma management.

Key clinical point: SABAs provide rapid symptom relief but should not replace anti-inflammatory controller medications in persistent asthma.

Long-Acting Beta-Agonists (LABAs): Maintenance Bronchodilator Therapy

Long-acting beta-agonists (LABAs) provide prolonged airway relaxation and maintain bronchodilation for approximately 12 hours or longer. They are used as maintenance medications to improve symptom control and reduce asthma-related limitations.

Common LABA Medications

Examples include:

• Salmeterol

• Formoterol

LABAs are commonly available in combination inhalers with inhaled corticosteroids, including:

• Fluticasone/salmeterol (Advair®)

• Budesonide/formoterol (Symbicort®)

Important Safety Considerations for LABAs

LABAs should:

• Be used only as maintenance therapy

• Not be used alone in asthma

• Always be combined with inhaled corticosteroids

LABA monotherapy is associated with increased risk of severe asthma-related outcomes because it improves airway symptoms without adequately controlling inflammation.

Combination ICS/LABA therapy improves asthma control by addressing both airway inflammation and bronchoconstriction.

Inhaled Corticosteroids (ICS): Foundation of Asthma Control

Inhaled corticosteroids are the preferred long-term controller medications for persistent asthma. They reduce airway inflammation, decrease mucus production, and improve airway responsiveness.

ICS therapy is considered the cornerstone of asthma treatment because it reduces:

• Asthma exacerbations

• Emergency department visits

• Hospitalizations

• Dependence on rescue inhalers

• Chronic airway inflammation

Common Inhaled Corticosteroid Medications

Examples include:

• Fluticasone (Flovent®)

• Budesonide (Pulmicort®)

• Beclomethasone (Qvar®)

Patient Education for ICS Use

Patients should be instructed to:

• Use ICS medications consistently as prescribed

• Understand that benefits develop gradually

• Rinse the mouth after inhalation to prevent oral candidiasis

Unlike rescue medications, ICS therapy is preventive and works by controlling the inflammatory process responsible for asthma symptoms.

Evidence-based statement: Regular use of inhaled corticosteroids significantly reduces asthma exacerbations and improves long-term disease control.

Long-Acting Muscarinic Antagonists (LAMAs) in Asthma Management

Long-acting muscarinic antagonists (LAMAs) are bronchodilators that block muscarinic receptors in airway smooth muscle. This action reduces bronchoconstriction and improves airflow.

Although LAMAs are primarily associated with COPD treatment, they may be added to asthma therapy when symptoms remain uncontrolled despite optimized inhaled corticosteroid and LABA treatment.

Common LAMA Medications

Examples include:

• Tiotropium (Spiriva®)

• Umeclidinium (Incruse Ellipta®)

• Glycopyrrolate

Role of LAMAs in Asthma

LAMAs may:

• Improve lung function

• Reduce airflow limitation

• Provide additional symptom control

However, they are not rescue medications and should not be used for immediate relief during acute asthma attacks.

Current Asthma Management Guidelines

Modern asthma treatment follows a stepwise approach that adjusts therapy according to symptom control and risk of exacerbations.

Two major evidence-based guideline sources include:

• Global Initiative for Asthma (GINA) recommendations

• National Asthma Education and Prevention Program (NAEPP) guidelines

Global Initiative for Asthma (GINA) Recommendations

Current GINA recommendations emphasize:

• Avoiding SABA-only treatment

• Using inhaled corticosteroid-containing therapy

• Considering as-needed low-dose ICS-formoterol for appropriate patients

• Regular assessment of asthma control

The goal is to provide sufficient medication to control symptoms while avoiding unnecessary treatment escalation.

National Asthma Education and Prevention Program (NAEPP) Guidelines

NAEPP guidelines use a step-based approach that considers:

• Asthma severity

• Symptom frequency

• Exacerbation history

• Medication response

Healthcare providers should regularly evaluate whether therapy should be increased or reduced.

Stepwise Asthma Pharmacologic Therapy

Asthma treatment is adjusted according to disease control.

Common medication classes include:

• Short-acting beta-agonists (SABAs) for rapid symptom relief

• Inhaled corticosteroids (ICS) for inflammation control

• LABA/ICS combinations for persistent symptoms

• LAMAs for selected uncontrolled asthma cases

• Leukotriene receptor modifiers for specific patient needs

Before changing therapy, clinicians should evaluate:

• Medication adherence

• Inhaler technique

• Environmental triggers

• Comorbid conditions

Patient Education and Self-Management Strategies

Successful asthma management requires more than medication alone. Patient education improves adherence and reduces preventable exacerbations.

Important education areas include:

Proper Inhaler Technique

Incorrect inhaler use can significantly reduce medication delivery to the lungs. Patients should receive repeated demonstrations and technique assessments.

Asthma Action Plans

A written asthma action plan helps patients identify:

• Daily controller medication use

• Early warning signs of worsening symptoms

• Steps to take during exacerbations

• When to seek emergency care

Monitoring Asthma Control

Patients may benefit from:

• Symptom tracking

• Peak flow monitoring when appropriate

• Regular follow-up appointments

Consistent monitoring allows early intervention and reduces the likelihood of severe asthma complications.

Chronic Obstructive Pulmonary Disease (COPD): Evidence-Based Diagnosis and Pharmacologic Management

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation, chronic airway inflammation, and structural changes within the lungs. The primary goals of COPD management are to reduce symptoms, prevent exacerbations, improve exercise tolerance, slow disease progression, and enhance quality of life through smoking cessation, bronchodilator therapy, pulmonary rehabilitation, and appropriate supportive care.

COPD commonly develops after long-term exposure to respiratory irritants, with cigarette smoking being the leading risk factor. Early diagnosis and evidence-based treatment can significantly reduce disease complications and improve survival, especially when combined with smoking cessation.

Understanding COPD Pathophysiology

COPD involves chronic inflammation and damage to the airways and lung tissue, leading to reduced airflow and difficulty exhaling.

The two major conditions associated with COPD are:

• Emphysema

• Chronic bronchitis

Both conditions contribute to airflow obstruction but differ in their clinical presentation and underlying lung changes.

Emphysema

Emphysema involves destruction of alveolar walls, resulting in reduced surface area for gas exchange and decreased lung elasticity.

Common characteristics include:

• Progressive shortness of breath

• Reduced exercise tolerance

• Hyperinflation of the lungs

• Barrel-shaped chest

• Pursed-lip breathing

• Thin body habitus

Historically, patients with emphysema were described as “pink puffers” because they often maintain oxygen levels until later stages of disease.

Chronic Bronchitis

Chronic bronchitis is characterized by excessive mucus production and chronic inflammation of the bronchial tubes.

It is clinically defined as:

• Productive cough occurring for at least three months in two consecutive years

Common findings include:

• Persistent mucus-producing cough

• Wheezing

• Frequent respiratory infections

• Cyanosis

• Peripheral edema

Historically, these patients were described as “blue bloaters” because of chronic hypoxemia and fluid retention.

COPD Diagnosis and Spirometry Testing

Spirometry is the gold standard diagnostic test for COPD. It measures lung function by evaluating airflow before and after administration of a bronchodilator.

A diagnosis of COPD is supported when:

Post-bronchodilator FEV1/FVC ratio is less than 0.70, indicating persistent airflow obstruction.

Important spirometry measurements include:

• Forced expiratory volume in one second (FEV1)

• Forced vital capacity (FVC)

• FEV1/FVC ratio

COPD Severity Classification Based on FEV1

While FEV1 helps classify airflow limitation, treatment decisions also depend on symptoms, exacerbation history, and overall patient health.

Goals of COPD Management

COPD treatment focuses on improving daily function while reducing disease-related complications.

Major treatment goals include:

• Reducing breathlessness

• Improving exercise capacity

• Preventing acute exacerbations

• Reducing hospital admissions

• Improving quality of life

• Slowing decline in lung function

The most important lifestyle intervention is smoking cessation.

Evidence-based statement: Smoking cessation is the single most effective intervention for slowing COPD progression and reducing mortality risk.

Pharmacologic Management of COPD

COPD medications primarily focus on improving airflow through bronchodilation. Unlike asthma, airway obstruction in COPD is not fully reversible; therefore, treatment aims to maintain lung function and reduce symptoms.

Major medication categories include:

• Long-acting beta-agonists (LABAs)

• Long-acting muscarinic antagonists (LAMAs)

• Combination bronchodilator therapy

• Methylxanthines in selected patients

• Corticosteroids during exacerbations

Long-Acting Beta-Agonists (LABAs) for COPD

LABAs stimulate beta-2 receptors in airway smooth muscle, producing prolonged bronchodilation.

Common LABA medications include:

• Salmeterol

• Formoterol

Benefits of LABA therapy include:

• Improved airflow

• Reduced shortness of breath

• Improved exercise tolerance

• Fewer COPD symptoms

LABAs are generally used as maintenance therapy rather than rescue medications.

Long-Acting Muscarinic Antagonists (LAMAs)

LAMAs block muscarinic receptors, reducing airway smooth muscle contraction and improving airflow.

They are considered first-line maintenance medications for many patients with COPD because they provide sustained bronchodilation.

Common LAMA Medications

Examples include:

• Tiotropium (Spiriva®)

• Umeclidinium

• Glycopyrrolate

Benefits of LAMA Therapy

LAMAs may:

• Improve lung function

• Reduce COPD symptoms

• Decrease exacerbation frequency

• Improve quality of life

Unlike short-acting bronchodilators, LAMAs are not intended for immediate symptom relief.

Combination Bronchodilator Therapy

Many patients with moderate-to-severe COPD require more than one bronchodilator to achieve adequate symptom control.

Combining medications with different mechanisms can provide greater improvement than using a single agent.

Examples include:

• LABA plus LAMA therapy

• Albuterol plus ipratropium (Combivent®)

Combination therapy may improve:

• Lung function

• Exercise ability

• Symptom control

• Exacerbation prevention

Treatment selection depends on symptom burden, exacerbation history, medication response, and tolerance.

Methylxanthines in COPD Treatment

Theophylline is an oral bronchodilator that may be considered in selected patients with severe COPD who remain symptomatic despite standard therapy.

However, its use has declined because of safety concerns.

Limitations include:

• Narrow therapeutic range

• Risk of toxicity

• Multiple drug interactions

• Need for blood level monitoring

Potential adverse effects include:

• Nausea

• Tremors

• Insomnia

• Cardiac arrhythmias

• Seizures in toxic levels

Because safer inhaled therapies are available, theophylline is usually reserved for specific clinical situations.

COPD Exacerbation Management

A COPD exacerbation is an acute worsening of respiratory symptoms that requires additional treatment.

Common symptoms include:

• Increased shortness of breath

• Increased cough

• Increased sputum production

• Changes in sputum color

Treatment commonly includes:

• Short-acting bronchodilators

• Systemic corticosteroids

• Antibiotics when bacterial infection is suspected

• Oxygen therapy when hypoxemia is present

Systemic Corticosteroids During COPD Exacerbations

Short courses of oral corticosteroids are commonly recommended during acute exacerbations.

A frequently used regimen includes:

• Prednisone 40 mg daily for approximately 5 days

Benefits include:

• Faster symptom improvement

• Improved lung function

• Reduced recovery time

• Lower risk of treatment failure

Long-term systemic corticosteroid use is generally avoided because of significant adverse effects.

Potential complications include:

• Osteoporosis

• Diabetes complications

• Muscle weakness

• Increased infection risk

• Adrenal suppression

Oxygen Therapy in COPD

Supplemental oxygen is used when COPD patients experience significant hypoxemia.

Indications for Oxygen Therapy

Oxygen may be recommended for:

• Acute COPD exacerbations with low oxygen levels

• Chronic severe resting hypoxemia

• Oxygen saturation approximately 88% or lower

Long-term oxygen therapy improves survival in selected patients with severe chronic hypoxemia.

However, oxygen should be prescribed based on clinical assessment because excessive oxygen administration may worsen carbon dioxide retention in some individuals with advanced COPD.

Pulmonary Rehabilitation and Lifestyle Management

Medication alone is not sufficient for optimal COPD management. Non-pharmacologic interventions improve function and reduce complications.

Important strategies include:

Smoking Cessation

Smoking cessation:

• Slows lung function decline

• Reduces COPD exacerbations

• Improves treatment response

• Improves survival outcomes

Pulmonary Rehabilitation

Pulmonary rehabilitation combines:

• Exercise training

• Breathing techniques

• Nutrition counseling

• Patient education

Benefits include:

• Improved exercise tolerance

• Reduced fatigue

• Better quality of life

Vaccination and Infection Prevention

Patients with COPD benefit from recommended vaccinations, including:

• Influenza vaccination

• Pneumococcal vaccination

• Other age-appropriate immunizations

Preventing respiratory infections reduces exacerbation risk.

Key Clinical Points for COPD Management

• COPD diagnosis requires spirometry confirmation.

• A post-bronchodilator FEV1/FVC ratio below 70% supports persistent airflow obstruction.

• Smoking cessation is the most effective intervention for slowing COPD progression.

• LAMAs and LABAs are central maintenance therapies for symptom control.

• Combination bronchodilator therapy may provide greater benefit than single-agent therapy.

• Systemic corticosteroids are useful for acute exacerbations but are not recommended for long-term maintenance.

• Oxygen therapy improves survival in patients with severe chronic hypoxemia.

• Pulmonary rehabilitation improves function and quality of life.

Pneumonia: Evidence-Based Diagnosis and Pharmacologic Management

Pneumonia is an infectious disease of the lung parenchyma caused by bacteria, viruses, fungi, or other microorganisms. Effective pneumonia management depends on identifying the likely pathogen, evaluating disease severity, selecting appropriate antimicrobial therapy, and considering patient-specific factors such as age, comorbidities, immune status, and local resistance patterns.

The clinical presentation of pneumonia varies widely, ranging from mild community-acquired infections treated in outpatient settings to severe infections requiring hospitalization and intensive care.

Understanding Pneumonia Pathophysiology

Pneumonia occurs when infectious organisms invade the lower respiratory tract, causing inflammation and accumulation of fluid or inflammatory cells within the alveoli. This process interferes with normal gas exchange and may result in hypoxemia.

Common causes include:

• Bacterial infections

• Viral respiratory infections

• Fungal infections

• Atypical organisms

Common clinical findings include:

• Fever

• Productive or nonproductive cough

• Shortness of breath

• Chest discomfort

• Fatigue

• Elevated white blood cell count

• Abnormal chest imaging findings

Chest radiographs may remain abnormal for several weeks after clinical improvement, especially in older adults or patients with severe pneumonia.

Community-Acquired Pneumonia (CAP) in Adults

Community-acquired pneumonia refers to pneumonia acquired outside healthcare facilities. Treatment selection depends on:

• Patient age

• Severity of illness

• Existing medical conditions

• Previous antibiotic exposure

• Local antimicrobial resistance patterns

Healthcare providers should assess whether the patient can be treated as an outpatient or requires hospitalization.

Adult Pneumonia Pharmacologic Treatment

Common antibiotic approaches for adults with community-acquired pneumonia include:

Beta-Lactam Plus Macrolide Therapy

A combination of a beta-lactam antibiotic with a macrolide may be used for patients with risk factors or comorbidities.

Examples include:

• Amoxicillin/clavulanate plus azithromycin

• Ceftriaxone plus azithromycin

This combination provides coverage against common bacterial pathogens and atypical organisms.

Respiratory Fluoroquinolones

Respiratory fluoroquinolones may be used in selected adult patients.

Examples include:

• Levofloxacin

• Moxifloxacin

• Gemifloxacin

These medications provide broad antimicrobial coverage but require consideration of potential adverse effects.

Possible risks include:

• Tendon injury

• QT prolongation

• Central nervous system effects

• Increased risk of certain complications in susceptible patients

Doxycycline Therapy

Doxycycline may be considered as an alternative option for appropriate adult patients.

It provides activity against:

• Streptococcus pneumoniae

• Atypical respiratory pathogens

Treatment decisions should always be individualized based on patient characteristics and clinical guidelines.

Pediatric Pneumonia Management

Pneumonia treatment in children depends heavily on age because the most likely pathogens change throughout childhood.

Pneumonia in Infants (4–16 Weeks)

In young infants, clinicians must consider organisms that are less common in older children.

A possible pathogen includes:

• Chlamydia trachomatis

Treatment options may include:

• Azithromycin

• Erythromycin

Careful monitoring is required because infants have a higher risk of complications.

Pneumonia in Children Younger Than Five Years

The most common bacterial cause in this age group is:

• Streptococcus pneumoniae

Treatment options may include:

• High-dose amoxicillin

• Ceftriaxone for severe disease

Alternative antibiotics may be considered for patients with medication allergies or specific clinical situations.

Pneumonia in Children Older Than Five Years

Older children are more likely to develop pneumonia caused by atypical organisms.

Common pathogen:

• Mycoplasma pneumoniae

Treatment options may include:

• Azithromycin

• Clarithromycin

• Erythromycin

Accurate diagnosis and appropriate antibiotic selection help reduce complications and antimicrobial resistance.

Tobacco Cessation: Pharmacologic and Behavioral Approaches

Tobacco dependence is a major preventable cause of respiratory disease, cardiovascular disease, and cancer. Smoking cessation is the most effective intervention for preventing COPD progression and improving respiratory health outcomes.

Nicotine addiction involves both physical dependence and behavioral patterns. Successful cessation programs typically combine medication therapy with counseling and behavioral support.

Benefits of Smoking Cessation

Stopping tobacco use can:

• Slow COPD progression

• Reduce respiratory symptoms

• Decrease cardiovascular risk

• Lower cancer risk

• Improve lung function decline

• Increase life expectancy

Even patients with established COPD benefit significantly from quitting smoking.

Nicotine Replacement Therapy (NRT)

Nicotine replacement therapy reduces withdrawal symptoms by providing controlled nicotine doses without harmful tobacco smoke exposure.

Common forms include:

Nicotine Patch

Provides continuous nicotine delivery throughout the day.

Benefits include:

• Simple dosing schedule

• Reduced cravings

• Improved adherence

Nicotine Gum

Provides short-acting nicotine replacement during cravings.

Patients should use proper chewing techniques to maximize absorption.

Nicotine Lozenges

Allow controlled nicotine absorption through the oral mucosa.

Nicotine Nasal Spray

Provides rapid nicotine delivery and may benefit individuals with strong cravings.

Non-Nicotine Tobacco Cessation Medications

Bupropion

Bupropion is an antidepressant medication that reduces nicotine cravings and withdrawal symptoms.

Benefits include:

• Reduced cigarette cravings

• Improved quit success rates

Potential adverse effects include:

• Insomnia

• Dry mouth

• Seizure risk in susceptible patients

Varenicline

Varenicline works by partially activating nicotine receptors while reducing nicotine reward.

Benefits include:

• Reduced cravings

• Reduced withdrawal symptoms

• Higher quit rates compared with placebo

Medication selection should consider patient preferences, contraindications, and previous quit attempts.

Behavioral Counseling for Smoking Cessation

Medication works best when combined with behavioral interventions.

Counseling strategies include:

• Identifying smoking triggers

• Developing coping strategies

• Setting quit dates

• Providing follow-up support

A combined medication and counseling approach produces the highest likelihood of long-term tobacco abstinence.

Tuberculosis (TB): Evidence-Based Pharmacologic Management

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It spreads primarily through airborne respiratory particles released when an infected person coughs, sneezes, or speaks.

Tuberculosis requires prolonged combination antibiotic therapy because using multiple medications prevents drug resistance and improves treatment success.

TB may occur as:

• Active tuberculosis disease

• Latent tuberculosis infection

Active Tuberculosis Treatment

Treatment of active TB usually involves multiple medications during an initial intensive phase followed by continuation therapy.

First-Line Tuberculosis Medications

The standard first-line medications include:

• Isoniazid (INH)

• Rifampin

• Pyrazinamide

• Ethambutol

This combination is commonly referred to as RIPE therapy.

Intensive and Continuation Phases of TB Therapy

Intensive Phase

The initial phase typically includes four medications:

• Isoniazid

• Rifampin

• Pyrazinamide

• Ethambutol

The goal is rapid reduction of bacterial load and prevention of resistance.

Continuation Phase

After the intensive phase, therapy usually continues with fewer medications depending on:

• Drug susceptibility results

• Clinical response

• Site of infection

Treatment duration commonly ranges from six months or longer depending on the clinical situation.

Monitoring During Tuberculosis Treatment

Because TB medications may cause significant adverse effects, regular monitoring is essential.

Monitoring may include:

• Clinical symptom assessment

• Sputum testing when indicated

• Liver function tests

• Kidney function monitoring

• Complete blood count

Isoniazid Monitoring

Isoniazid may cause:

• Hepatotoxicity

• Peripheral neuropathy

Patients at increased risk of neuropathy may receive:

• Pyridoxine (vitamin B6) supplementation

Rifampin Considerations

Patients should be educated that rifampin may cause:

• Orange discoloration of body fluids

• Multiple medication interactions due to enzyme induction

Ethambutol Monitoring

Ethambutol may affect vision.

Patients should be monitored for:

• Changes in visual acuity

• Color vision abnormalities

Latent Tuberculosis Infection Management

Latent TB infection occurs when a person has evidence of TB exposure but does not have symptoms or active disease.

Patients with latent TB:

• Do not spread TB

• Have a future risk of developing active disease

Treatment reduces the likelihood of progression.

Management includes:

• Appropriate preventive medication therapy

• Regular monitoring

• Patient education

• Assessment for medication adverse effects

Key Clinical Takeaways

• Asthma management should prioritize inhaled corticosteroid-containing therapy to control airway inflammation.

• SABAs provide rapid symptom relief but should not be used as the only asthma treatment.

• LABAs should always be combined with inhaled corticosteroids when used for asthma.

• COPD diagnosis requires spirometry confirmation, with a post-bronchodilator FEV1/FVC ratio below 70% supporting airflow obstruction.

• Smoking cessation is the most effective intervention for slowing COPD progression.

• COPD maintenance therapy commonly includes LABAs, LAMAs, or combination bronchodilators.

• Pneumonia treatment depends on age, severity, comorbidities, and suspected pathogens.

• Tobacco cessation is most successful when medication therapy is combined with counseling.

• Tuberculosis requires multidrug therapy, adherence monitoring, and laboratory evaluation to prevent resistance.

• Patient education and follow-up are essential components of respiratory disease management.

Frequently Asked Questions (FAQs)

What is the most important medication for long-term asthma control?

Inhaled corticosteroids are the foundation of long-term asthma treatment because they reduce airway inflammation, prevent exacerbations, and improve disease control.

Can LABA medications be used alone for asthma?

No. LABAs should not be used alone in asthma because they do not control airway inflammation. They should be combined with inhaled corticosteroids.

How is COPD diagnosed?

COPD is diagnosed using spirometry. A post-bronchodilator FEV1/FVC ratio below 70% indicates persistent airflow limitation consistent with COPD.

What is the most effective treatment to slow COPD progression?

Smoking cessation is the most effective intervention for slowing COPD progression and reducing mortality risk.

What antibiotics are commonly used for pneumonia?

Treatment depends on the patient and suspected organism. Common options include beta-lactam antibiotics, macrolides, doxycycline, and respiratory fluoroquinolones when clinically appropriate.

Why does tuberculosis require multiple medications?

TB requires combination therapy because using multiple drugs prevents the development of antibiotic resistance and improves treatment effectiveness.

How long is tuberculosis treatment?

Most tuberculosis treatment courses last approximately six months, although duration may vary depending on disease location, drug resistance, and patient response.

References

Centers for Disease Control and Prevention. (2025). Tuberculosis (TB): Clinical care and treatment.
https://www.cdc.gov/tb

Centers for Disease Control and Prevention. (2024). Smoking and tobacco use: Quitting smoking.
https://www.cdc.gov/tobacco

Global Initiative for Asthma. (2025). Global strategy for asthma management and prevention.
https://ginasthma.org

NU553 Asthma Lecture Notes

Global Initiative for Chronic Obstructive Lung Disease. (2025). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
https://goldcopd.org

Metlay, J. P., Waterer, G. W., Long, A. C., et al. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 200(7), e45–e67.
https://doi.org/10.1164/rccm.201908-1581ST

National Heart, Lung, and Blood Institute. (2020). 2020 focused updates to the asthma management guidelines.
https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines